New study aims to make bile duct drainage safer
NCT ID NCT06620328
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two methods for widening a blocked bile duct during a special endoscopy procedure. One method uses a mechanical dilator, the other uses an electrocautery device. The goal is to see which causes less bleeding. The trial will involve 64 patients who cannot have standard ERCP or have other reasons for this approach.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a safer, less risky way to drain blocked bile ducts during endoscopy.
- What could go wrong
- This is a small, early-stage trial with only 64 participants, so results may not apply to everyone. The main risk is bleeding, which is what the study is trying to reduce.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Failed ERCP * The papilla is inaccessible owing to a surgically altered anatomy or gastric outlet obstruction * Contraindications for PTCD such as ascites and possibility of self-tube removal Exclusion Criteria: * Patients younger than 18 years old * Cancer infiltration of the gastric/duodenal wall within the planned puncture route * Patients with uncorrectable coagulopathy * Patients with unmanageable ascites * Patients with serious comorbidities that prohibited endoscopic management * Patients with pregnancy * Patients who cannot or refuse to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Biliary obstruction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New device aims to make pancreatic and bile duct procedures safer
- Dissolving stent could unblock bile ducts without extra surgery
- Which sedation works best for bile duct procedures? new study aims to find out
- Which stent is best for unblocking bile ducts in cancer patients?
- Extra fluids during ERCP may prevent pancreatitis, study finds
- New approach: antibiotics delivered straight to the infection site during ERCP